#None #Amgen #Cardiovascular #Repatha

Amgen's New Milestone in Cardiovascular Health

In a significant advancement in cardiovascular treatment, Amgen (NASDAQ: AMGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for its drug Repatha® (evolocumab). This decision paves the way for broader use of Repatha in preventing the first occurrence of heart attacks and strokes in adults at established or high risk for atherosclerotic cardiovascular disease (ASCVD).

Significance of the Positive Opinion

The endorsement from the CHMP is based on the promising results from the global phase 3 VESALIUS-CV study, which involved over 12,000 patients. The study demonstrated that Repatha significantly lowers the risk of major cardiovascular events (MACE) in adults who have not previously experienced myocardial infarction or stroke. Paul Burton, M.D., Ph.D., Chief Medical Officer at Amgen, emphasized the unmet need in Europe where a substantial number of high-risk patients struggle to achieve optimal LDL cholesterol levels with existing lipid-lowering therapies.

Understanding Repatha's Mechanism

Repatha is the only PCSK9 inhibitor that has shown, in clinical trials, a notable reduction in the risk of first severe cardiovascular events. Its mechanism involves inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9), which subsequently increases the number of low-density lipoprotein receptors (LDLR) on liver cells, subsequently clearing more LDL cholesterol from the blood.

VESALIUS-CV Study Insights

The VESALIUS-CV study was a double-blind, randomized, placebo-controlled trial that assessed the impact of LDL-C reduction through evolocumab on serious cardiovascular outcomes. The study's findings, published in the _New England Journal of Medicine_ in November 2025, revealed that Repatha achieved a relative risk reduction of 25% in composite outcomes related to ischemic heart disease and a substantial 36% reduction in heart attack risk. These compelling statistics highlight the drug's effectiveness in managing high cardiovascular risk.

Over the course of the study, participants' mean baseline LDL-C was recorded at 122 mg/dl, and those treated with evolocumab experienced a dramatic reduction in LDL-C levels, underscoring the drug's cholesterol-lowering efficacy.

A New Standard for Treatment

The CHMP's positive opinion takes Amgen a step closer to making Repatha accessible to more patients who could benefit from its capabilities in reducing cardiovascular risk. This could redefine cardiovascular care strategies in Europe, particularly for patients unable to achieve target LDL levels with existing treatments.

Originally approved in the European Union in 2015, Repatha has undergone significant scrutiny and validation, establishing its role not only in treating primary hypercholesterolemia but also in cardiovascular risk reduction among high-risk adult populations. With this broader indication, the drug can address a critical gap in treatment options for patients at various stages of cardiovascular risk.

Future Considerations and European Commission's Decision

Amgen expects that the European Commission will make a final decision regarding the expanded indication in the coming months, which could potentially revolutionize preventive health strategies for cardiovascular diseases. Given that cardiovascular diseases remain a leading cause of mortality worldwide, the outcomes of this evaluation are eagerly awaited by both medical professionals and patients alike.

Commitment to Cardiovascular Innovation

Amgen’s dedication to innovative cardiovascular care is demonstrated by its utilization of cutting-edge scientific knowledge derived from human biology and its focus on intricate interrelations between cardiovascular and metabolic diseases. The firm aims to continue its legacy in developing groundbreaking therapies that address not just symptoms, but the root causes of these serious health challenges.

With continued efforts in research and development, including potential future therapies like MariTide and olpasiran, Amgen is poised to provide comprehensive solutions to the multifactorial challenges of cardiovascular disease management.

Through its innovative approach to health care, which blends advanced scientific techniques with a deep understanding of genetic factors, Amgen is leading the way in redefining how cardiovascular diseases are treated and managed.